PHOENIX CHILDRENS HOSPITAL
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $17M
- Transactions
- 2,847
- Companies
- 40
- Average per transaction
- $5,957
Who reported the payments
| Novartis | $1,608,873 |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,353,407 |
| Jazz Pharmaceuticals Inc. | $1,326,308 |
| Pfizer | $1,211,517 |
| Regeneron | $939,564 |
| Amgen | $762,322 |
| AstraZeneca | $636,341 |
| Ultragenyx Pharmaceutical Inc. | $580,996 |
| E.r. Squibb & Sons, L.L.C. | $572,424 |
| Sanofi US Services Inc. | $403,353 |
| Eli Lilly | $386,623 |
| Agios Pharmaceuticals, Inc. | $382,610 |
| Gilead | $344,343 |
| AbbVie | $341,523 |
| Genentech, Inc. | $322,090 |
| Philips North America LLC | $309,829 |
| Chiesi USA, Inc. | $307,708 |
| Biomarin Pharmaceutical Inc. | $299,858 |
| PTC Therapeutics, Inc. | $278,228 |
| CSL Behring | $274,299 |
| Cerus Corporation | $263,495 |
| Sumitomo Pharma America, Inc. | $259,667 |
| Acadia Pharmaceuticals Inc | $247,283 |
| Shire North American Group Inc | $245,136 |
| Janssen Research & Development, LLC | $236,728 |
| Bristol Myers Squibb | $211,473 |
| Global Blood Therapeutics, Inc. | $191,059 |
| Bioverativ Therapeutics Inc. | $178,620 |
| Merck | $168,122 |
| Sanofi | $160,075 |
| SK Life Science, Inc. | $145,017 |
| Boehringer Ingelheim | $138,843 |
| Novo Nordisk AS | $132,469 |
| GE HealthCare | $96,048 |
| Daiichi Sankyo Inc. | $90,000 |
| W. L. Gore & Associates, Inc. | $84,064 |
| Blueprint Medicines Corporation | $74,648 |
| Kls-martin L.p. | $72,000 |
| Guerbet LLC | $69,432 |
| Exeltis, USA Inc. | $67,883 |